An hiPSC-CM approach for electrophysiological phenotyping of a patient-specific case of short-coupled TdP Authors: Willem B van Ham, Esmeralda E M Meijboom, Merel L Ligtermoet, Jantine Monshouwer-Kloots, Anneline S J M te Riele, Folkert W Asselbergs, Eva van Rooij, Mimount Bourfiss, Toon A B van Veen Published: 2024 ABSTRACT AbstractIntroductionA healthy young woman, age 26 without prior cardiac complications, experienced an out-of-hospital cardiac arrest caused by ventricular fibrillation (VF), which coincided with a fever. Comprehensive diagnostics including echo, CMR, exercise testing, and genetic sequencing, did not identify any potential cause. This led to the diagnosis of idiopathic VF and installment of an implantable cardioverter defibrillator, which six months later appropriately intervened another VF episode under conditions comparable to the first event. A second diagnostic opinion concluded short-coupled Torsade de Pointes (scTdP), and the patient was started on a verapamil treatment.MethodsFrom this patient, human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) lines were generated to study cellular electrophysiology. Without a known genetic pathogenic variation, no isogenic control line could be produced, therefore a healthy age- and sex-matched control hiPSC-CM line was used. Cellular electrophysiology was studied in these cardiomyocytes using calcium- and voltage sensitive fluorescent dyes and measurements were carried out at 37 °C and 39 °C, to mimic the condition of hyperthermia in the patient. mRNA expression of electrophysiologically relevant genes were analyzed to identify a potential underlying mechanism.ResultsCalcium transients measured in patient lines at a physiological temperature indicated the occurrence of early after transients (EATs). Strikingly, at 39 °C the incidence of EATs further increased. Membrane potential data from the patient also revealed shorter action potentials that, combined with the EATs, indicate the premature release of calcium during diastole, which could be responsible for the extrasystoles in the patient. Gene expression profiles were mainly downregulated in the patient but could not clearly aid in unraveling a mechanism behind the occurrence of EATs. Pharmacological screening was performed to evaluate the treatment regimen and to determine a mechanism of action of the EATs. While verapamil, dantrolene, and flecainide did not decrease the incidence of EATs, calcium handling parameters were affected indicating functionality of the drugs.ConclusionThis patient-specific case of electrophysiological phenotyping resulted in a hypothesis of the possible mechanism behind the scTdP arrhythmias, but also accentuates the applicability of patient-specific hiPSC-CM disease modeling and phenotyping.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13287-024-04074-8.Keywords: Short-coupled Torsade de Pointes, hiPSC-CM, Patient-specific, Phenotyping, Calcium handling dysfunction Introduction Inherited and acquired cardiomyopathies and cardiac channelopathies include a considerable number of cardiac diseases with various genetic predisposition, disease progression, and clinical presentation [1–4]. Unfortunately, the most common and often first symptom in arrhythmogenic forms of cardiomyopathy is sudden cardiac death (SCD), caused by severe cardiac arrhythmias. These diseases are often introduced due to genetic variations, including complex variations like compound and digenetic heterozygosity [5]. However, a primary clinical phenotype can also be present in patients without (or unknown) genetic predisposition [6, 7]. The unlimited use of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) has facilitated numerous possibilities for physiological studies, disease modeling and phenotyping, and pharmacological safety screenings. Studying patient-specific hiPSC-CM models can aid in understanding not only the mechanism underlying a disease phenotype, but it also provides a method to predict potential clinical presentations based on experimental phenotypes. Additionally, it might help to identify relatives at risk [8]. At the basis of cardiac arrhythmias stands the dysregulation of the cardiac action potential (AP) and calcium handling within the cardiomyocytes [9]. Conduction of the AP across the myocardium activates the cardiomyocytes in a synchronized manner, followed by the calcium release from the sarco-endoplasmic reticulum (SR) within the individual cells, which then results in the contraction of the myocardial tissue [10]. Any of these processes can be disrupted by decreased or increased function of the proteins involved. Pharmacological interventions can be applied to modulate the effects of disturbed ion transport, by blocking, altering kinetics, or activating different ion channels and transporters. In this study we included a 26-year-old female patient without prior cardiac (or related) family history, who suffered from an out of hospital sudden cardiac arrest due to ventricular fibrillation (VF) while she was having a fever. Extensive clinical diagnostics, including cardiac echo and cardiac magnetic resonance imaging (CMR), genetic sequencing, and exercise testing, did not identify a cause for the VF. The ectopy originated from the lower left septal segment and was therefore suggested to be Purkinje fiber related. Given the fact that no extensive electrophysiological testing has been performed this could however not be confirmed. The patient was diagnosed with short-coupled Torsade de Pointes (scTdP). An implantable cardioverter defibrillator (ICD) was implanted, which several months later had to intervene another VF during a second period of hyperthermia. The ICD interrogation of the minute prior to the interventional shock included a VF episode befitting to the scTdP diagnosis (Fig. 1). Both a self-terminating VF and the intervened VF episode were initiated by short coupled ectopic activity. Additionally, several extrasystoles preceded the arrhythmias in this brief timespan. The patient was instrumented on verapamil. Blood was taken from the patient and hiPSC-CMs were produced. In the absence of an identified genetic variation, a healthy age- and sex-matched donor was used a control. Intervention of ventricular fibrillation as seen on the ICD interrogation of the patient. Electrical signal as detected by the implantable cardioverter defibrillator (ICD) of the patient, consisting of a regular rhythm, independent extrasystoles, a self-terminating ventricular fibrillation (VF), and the intervened VF. 5 subsequent squares represent a timespan of 1 s. The lighting symbol represents the moment of the ICD shock. Letters underneath the interrogation represent sensing (S), tachycardia (T), capacitor charging/charged (C), post-shock pacing (P), unclassified event (•), noise (N) We investigated the experimental electrophysiological phenotype of the hiPSC-CMs of the patient and a healthy individual, in an attempt to discover a potential mechanism for the VF occurrence in the patient. We were able to identify a calcium handling disturbance, which was even worsened by a hyperthermic condition, while pharmacological interventions did not alleviate the calcium handling disruptions. The ensemble of electrophysiological effects resulted in a hypothesis of the possible mechanism behind the scTdP arrhythmias, but also accentuates the applicability of patient-specific hiPSC-CM disease modeling and phenotyping. Methods Drugs Dantrolene (Sigma-Aldrich, D9175) and flecainide (Sigma-Aldrich F6777) were dissolved in DMSO to 10 mM, filtered, and stored at – 20 °C. Verapamil (Centrafarm) was diluted at 2.5 mg/mL HCl and stored at room temperature. Drugs were added to the culture medium for 24 h prior to experiments, DMSO was used for vehicle measurements. Generation of human iPSC clones iPSC lines were commercially generated through episomal reprogramming of isolated peripheral blood mononuclear cells derived from the patient and a healthy age- and sex-matched control at the Leiden University Medical Center hiPSC core facility. Episomal reprogramming was performed as described previously [11]. Pluripotency vectors included NANOG, SSEA4, and OCT3/4, and FACS characteristics are also shown in Figure S1. Three independent clones were produced for the patient and one clone for the healthy individual. Clones were obtained frozen in liquid nitrogen. Bulk karyo-sequencing ± 1000 hiPSCs were collected as pellet to which 5 µl of 2 µg Proteinase K (NEB) in 1 × CutSmart Buffer (NEB) was added for 2 h at 55 °C followed by 10 min at 80 °C. DNA was digested using 10 µl of 10 U NLAIII (NEB) in 1 × CutSmart Buffer for 2 h at 37 °C followed by 20 min at 80 °C. DNA fragments were ligated to adapters by adding 20 µl of 800 U T4 DNA ligase (NEB), 1 mM ATP (ThermoFisher) and 50 nM adapter in 1 × T4 DNA ligase buffer (NEB) and incubating at 16 °C overnight. The library preparation, sequencing and analysis was performed as described previously [12]. Cell culture hiPSCs were cultured on Geltrex-coated wells (Gibco, A1413302). Cells were refreshed daily with Essential 8 Medium (Gibco, A1517001), and passaged once they reached 80–100% confluency. Briefly, medium was aspirated, and TrypLE Express Enzyme (Gibco, 12605010) was added for 5 min at 37 °C. After incubation, 4 mL of Essential 8 Medium, supplemented with 1 µM thiazovivin (Sigma-Aldrich, 420220), was added to the dissociated cells and the cell suspension was transferred to a 15 mL Falcon tube. Cells were centrifuged at 300 RCF for 3 min. Subsequently, cells were seeded at a density of 15.000 cells/cm2 in Essential 8 Medium, supplemented with 1 µM thiazovivin. Medium was refreshed the next day with plain Essential 8. Cardiomyocyte differentiation hiPSCs were grown until 80–90% confluency and washed once with dPBS (Gibco, 14190094). Cells were then cultured with RMPI + + (bare RPMI-1640-Medium-GlutaMAXSupplement-HEPES (Gibco, 72400-021) supplemented with 0.5 mg/mL human recombinant albumin (Sigma-Aldrich, A9731) and 0.2 mg/mL L-Ascorbic Acid 2-Phosphate (Sigma, A8960)), added with 4 µM CHIR99021 (Sigma, 361559). After 48 h, medium was replaced with RMPI + + added with 5 µM IWP2 (Sigma, 681671), following a single rinse with bare RMPI-1640. Cells were then refreshed every other day with RMPI + + , for four days. From there, cells were cultured every three to four days with complete RMPI medium (bare RMPI-1640, supplemented with B-27 Supplement (Gibco, 17504001)). Then, to increase cardiomyocyte purity, complete RMPI medium was replaced with selection medium (RPMI 1640 without glucose and without HEPES (Biological Industries, 01-101-1A), added with 4 mM lactate (Chemcruz SC-301818A), 3.5 mM HEPES (Sigma H0887), and B-27 supplement) [13]. After four days of selection, historically reaching a purity of 90–95%, cells were placed in complete RMPI medium, supplemented with 1% penicillin–streptomycin (Thermo Fisher Scientific 15140122). Prior to optical experiments, the hiPSC-CMs were dissociated with TrypLE Select Enzyme without phenol red (Gibco, A1217703) and seeded on Geltrex-coated coverslips. Three to four independent differentiations were produced of each hiPSC line. Optical electrophysiology hiPSC-CMs were seeded at a density of 150.000 cells per Geltrex-coated coverslip to allow formation of monolayered clusters. Coverslips were incubated with either Powerload and FluoVolt (ThermoFisher, F10488, 1:1000) or Fluo-4-AM (ThermoFisher, F14201, 1:1000) in complete RMPI medium for 20 min at 37 °C. Clusters were recorded at 37 °C and 39 °C (the latter to mimic fever) during which the coverslips were placed in a bath solution containing (mM): NaCl (130), KCl (4), CaCl2 (1.8), MgCl2 (1.2), NaHCO3 (18), HEPES (10), Glucose (10), with pH 7.4. Fluorescent signals were recorded using a custom-built microscope (Cairn Research, UK) using a 10 × objective. Blue light was filtered using an excitation filter (482/35 nm) and projected on the objective with a dichroic mirror (515 nm). Fluorescent signals were captured, via a long-pass emission filter (514 nm), by a high-speed camera (Andor Zula 5.5.CL3). Analysis of the data was performed using Fiji and Peaks, a custom-written Matlab script (10.17605/OSF.IO/86UFE). Analyzed signals of the spontaneously beating hiPSC-CMs were then adjusted for beating rate using a modified Fredericia’s correction: APDcorrected = APD/(∛(60/BPM). Quantitative PCR Total RNA was isolated from hiPSC-derived cardiomyocytes using the RNeasy Mini Kit (Qiagen, 74104) following the protocol supplied by the manufacturer. Total RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Bio Rad, 1708891). Quantitative PCR (qPCR) reactions were performed on a Bio Rad CFX96 Real-Time PCR Detection System using the iQ SYBR Green Supermix kit (Bio Rad, 170-8885). Primers used for amplification can be found in Table S1. The 2(−ΔΔCT) method was used to analyze the data. Statistical analysis All statistical analysis was executed using GraphPad Prism v.9 software. Comparisons were analyzed using a Student’s T-test (action potential data), One-Way ANOVA, with Tukey’s post-hoc test to correct for multiple comparisons (mRNA expression data) or Two-Way ANOVA, with Tukey’s post-hoc test to correct for multiple comparisons (calcium handling data). Data is shown as individual datapoints. Results Electrophysiological disturbances In order to uncover a potential cause for the ventricular arrhythmias experienced by the patient (Fig. 1), hiPSCs were generated from the patient and an age- and sex-matched healthy control. hiPSC characterization and karyotyping data are shown in Figure S1. Optical screening of calcium transients (CaTs) was performed using a fluorescent calcium sensitive dye, which resides in the cytosol. Release of SR calcium via the ryanodine receptor (RyR2) and removal via mainly the sarco-endoplasmic reticulum calcium ATPase (SERCA2A) and the sodium-calcium exchanger (NCX1) are represented in recordings as peak up- and downstrokes, respectively. In the hiPSC-CMs monolayered clusters of the patient, initial calcium releases were followed by additional releases, which were defined as early after transients (EATs) (Fig. 2A). Under normothermic conditions, these EATs were observed in 8.14% of the measurements in the patient, compared to 0% in the healthy control cells (Fig. 2B). The occurrence of these EATs was even further increased during hyperthermia, resulting in 17.99% EATs in the measurements in the patient, compared to 2.94% in the healthy control. Interestingly, the single EAT in the control line that was observed in only one CaT during the recording and displayed an amplitude that was smaller than the initial calcium release. However, the recorded EATs originating from the patient lines mainly occurred in every CaT of those recordings, while also having amplitudes that matched the original released ones (Figure S2). Occurrence of early after transients in patient hiPSC-CMs. Calcium transient measurements were performed in hiPSC-CMs from the patient and a healthy control during normo- and hyperthermia. A During measurements of hiPSC-CMs of the patient extra calcium releases, termed early after transients (EATs), were observed during normo- and hyperthermia. B Quantification of the EATs highlighted the increased occurrence in the patient, especially after hyperthermia. N = number of measured cell clusters, originating from one clone (healthy) and 3 clones (patient) each with 3–4 hiPSC-CM differentiations Morphology of CaTs were analyzed to quantify release and removal times of cytosolic calcium in these measurements (Fig. 3A). An increased number of calcium releases, as well as increased amplitudes were detected in the patient, without displaying a prolonged release time (Fig. 3B–D). Both cytosolic calcium removal and total CaT duration were lengthened in cells from the patient, which was seen at a regular temperature and during hyperthermia (Fig. 3E, F). This was mainly driven by extreme CaT durations corresponding to EAT measurements. Calcium transient parameters indicating disturbed calcium handling. Calcium transient measurements were performed in hiPSC-CMs from the patient (red) and a healthy control (black) during normo- and hyperthermia. A Definitions of parameters based on the amplitude, and 10% and 90% of the up- and downstroke of the fluorescence intensity. B Number of signals per minute (SPM). C Amplitude of the initial calcium signal, representing the amount of calcium in the initial release. D Rise time of the calcium signal, representing the release time of calcium into the cytosol. E Decay time of the calcium signal, representing the removal time of calcium from the cytosol. F 90% of the calcium transient duration (CTD), representing the duration of the entire calcium transient. N = 34–221 measured cell clusters, originating from one clone (healthy) and 3 clones (patient) each with 3–4 hiPSC-CM differentiations In the control and patient lines, action potential duration (APD) was also measured using a voltage-sensitive dye, at both normo- and hyperthermia (Figure S3). Analysis of the AP fluorescence signal was performed, with the depolarization and repolarization as peak up- and downstrokes, respectively (Fig. 4A). In the cells from the patient, spontaneous beating rates (Fig. 4B) were similar when compared to those recorded during CaT measurements (Fig. 3B). The beating rate of healthy and patient hiPSC-CMs in the APD measurements was similar (Fig. 4B). Interestingly, action potential repolarization was shorter in the patient (Fig. 4C, D). Together, these data suggest electrophysiological disturbances that could underly the clinical phenotype of the patient, strengthened by an aggravation of the disturbed calcium handling by a hyperthermic condition. Shortened action potentials in patient hiPSC-CMs. Action potential measurements were performed in hiPSC-CMs from the patient (red) and a healthy control (black) during normo- and hyperthermia. A Definitions of parameters based on 50% and 90% of the downstroke of the fluorescence intensity. B Number of signals per minute (SPM). C 50% of the action potential duration (APD), representing early repolarization. D 90% of the APD, representing total repolarization. N = 47–135 measured cell clusters, originating from one clone (control) and 3 clones (patient) each with 3–4 hiPSC-CM differentiations Gene expression profile While no pathogenic genetic variations were identified in the patient, studying gene expression could aid in identifying a cause for the occurrence of the EATs. Therefore, mRNA expression of electrophysiologically relevant genes was quantified in multiple clones and differentiations of the two individuals (Figure S4). mRNA expression of many important calcium handling proteins was significantly decreased, including RyR2, SERCA2a, phospholamban (PLN), L-type calcium channel (CaV1.2), NCX1, and the calcium/calmodulin dependent kinase (CAMK2), or showed a trend towards downregulation, such as calsequestrin (CSQ2). mRNA expression of proteins involved in the formation of the AP were also decreased, including the rapid component of the potassium repolarization current (KV11.1) and the depolarizing sodium current (NaV1.5). mRNA expression of the potassium current mainly responsible for the stabilization of the resting membrane potential (KIR2.1) was also seemingly lower in the patient, but is known to be close to absent as generally reported in all hiPSC-CMs [14]. Overall, the majority of important genes involved in cellular electrophysiology and calcium handling was significantly downregulated in the patient. Hampered pharmacological screening To investigate the effects of several drugs on the mechanisms behind the observed and aberrant EATs, cells from the two individuals were incubated with 5.5 µM verapamil (a CaV1.2 blocker), 10 µM dantrolene (a RyR2 blocker), or 10 µM flecainide (a NaV1.5 blocker) for 24 h. CaTs were measured under hyperthermic conditions, and the occurrence of EATs was quantified. While only 1 EAT was observed in each of the four conditions using control cells (4–6.25%), the number of EATs in the patient at hyperthermia with vehicle administration (15.52%, Fig. 5) was comparable compared to the previous baseline experiments (17.99%, Fig. 2). Verapamil (20.75%), dantrolene (24.49%), and flecainide (17.50%) even further increased the incidence of EATs (Fig. 5), which indicates a more profound disruption of the calcium kinetics in the hiPSC-CMs of specifically the patient. Occurrence of early after transients after pharmacological intervention. Calcium transient measurements were performed in hiPSC-CMs from the patient and a healthy control during hyperthermia after 24 h incubation with either verapamil (5.5 µM), dantrolene (10 µM), flecainide (10 µM), or a vehicle (DMSO). Compared to the prior experiment, the occurrence of early after transients (EATs) after drug administration did not alter in the vehicle group, while the patient had a similar or increased percentage of EATs. N = number of measured cell clusters, originating from one clone (control) and 3 clones (patient) each with 3–4 hiPSC-CM differentiations Quantification of the CaTs partly supported the effects of verapamil and dantrolene. Although the number of calcium signals per minute (SPM) and amplitude did not differ between healthy and patient cells, the number of SPM seemed to be lower for the patient (Fig. 6A, B) when compared to the initial set of calcium experiments (Fig. 3B). However, release time was increased after verapamil administration in the patient, but otherwise similar or even shortened compared to previous measurements (Fig. 6C). The CaT length was only influenced by dantrolene, which resulted mainly from those measurements that displayed extreme EATs (Fig. 6D, E). Additionally, while no drug was able to decrease the occurrence of EATs, amplitude of EATs seemed to be diminished in a majority of the measurements (Figure S5). All combined, the applied pharmacological screening did not result in improved calcium regulation, but in contrast even worsened the situation of disturbed calcium handling. Calcium transient parameters after drug administration. Calcium transient measurements were performed in hiPSC-CMs from the patient (red) and a healthy control (black) during hyperthermia after 24 h incubation with either verapamil (5.5 µM), dantrolene (10 µM), flecainide (10 µM), or a vehicle (DMSO). A Number of signals per minute (SPM). B Amplitude of the initial calcium signal, representing the amount of calcium in the initial release. C Rise time of the calcium signal, representing the release time of calcium into the cytosol. D Decay time of the calcium signal, representing the removal time of calcium from the cytosol. E 90% of the calcium transient duration (CTD), representing the duration of the entire calcium transient. N = 15–58 measured cell clusters, originating from one clone (control) and 3 clones (patient) each with 3–4 hiPSC-CM differentiations Discussion In this study, we generated hiPSC-CMs from a patient who was successfully resuscitated from an out of hospital sudden cardiac arrest due to ventricular arrhythmias without a known cause. The cardiac arrest occurred under conditions of fever. In the absence of a known genetic variation in the patient, hiPSC-CMs were produced from a healthy age- and sex-matched control. Upon evaluating calcium handling in all hiPSC-CM lines, we found a striking occurrence of premature calcium releases (EATs) in the patient under normothermic conditions, which robustly increased under hyperthermic conditions. Further analysis of action potentials in the patient indicated a shortened APD, again both in normo- and hyperthermia. In general, mRNA expression of electrophysiologically crucial genes was also diminished in the patient, which cannot convincingly uncover a mechanism behind the EAT occurrence. We then performed a pharmacological screening to further study the proarrhythmic mechanism initiating the EATs, as well as to evaluate the effect of the current clinical treatment in the patient. Drug regimen was focused on controlling extracellular calcium load via CaV1.2 (by application of verapamil) and SR-calcium release (by application of dantrolene and flecainide). In contrast to what was expected, neither verapamil, dantrolene, nor flecainide ameliorated the incidence of EATs and even further perturbed the disturbed calcium handling, although it did seem to affect the calcium handling in terms of decreased amplitude and slowed CaT duration. In contrast, treatment of the healthy cells with those drugs did not worsen outcome. This study highlights the potential of patient-specific application and disease phenotyping using hiPSC-CMs. Short-coupled torsade de pointes As extra calcium is being released from the SR (EATs) without being triggered by a new AP, which can occur when the cardiac membrane potential is either still depolarized or completely repolarized, it can cause early or delayed after depolarizations (EADs and DADs), respectively [15]. These EADs and DADs are prematurely triggered action potentials, and in case that SR-calcium release is involved, are caused by increasing inward sodium current via the NCX1 in return for an outward calcium flux [16, 17]. In the experimental data from our patient, both APD shortening and EATs are observed, creating the ideal circumstance for DAD formation, which could result in triggered activity in the form of premature ventricular complexes (PVCs) and VF [18, 19]. However, it is important to note that the electrophysiological immaturity of hiPSC-CMs is mainly noticeable in the shorter AP, which could mean that the EATs observed in our study, might result in either EADs or DADs. Within our AP measurements we did not observe any DAD-like peaks; however, within spontaneously active hiPSC-CMs it is difficult to determine which signals are DAD-triggered action potentials. Both EADs and DADs have been hypothesized as cause for the development of scTdP, although EADs are thought to be more likely since patients often have normal QT intervals. As PVCs prior to the TdP are short coupled, it would require an early triggered AP [20–22]. The PVCs present prior to scTdP in patients often originate from the Purkinje fiber network, which are especially likely to result in VF [21, 23]. As this seems to be the case in our patient, the experienced VF episodes developed are with a high degree of plausibility caused by early membrane depolarizations due to triggered extra calcium release from the SR. The use of verapamil has been shown to be effective in decreasing TdP occurrence, while not reducing the risk of SCD, leaving ICD implantation as advisable treatment [20, 22, 24, 25]. Whether the hyperthermia in the patient has acted as a secondary trigger remains unresolved. Pharmacological screening in diseased hiPSC-CMs The pharmacological intervention, using verapamil, dantrolene, and flecainide, did not decrease the occurrence of EATs in the patient lines. While to a certain extend these drugs did show to be effective, all have limitations in term of preventing EATs. Verapamil is a CaV1.2 blocker that can inhibit or delay calcium-induced calcium release (CICR), by lowering the calcium availability in the dyad between T-tubules and the SR. Blocking this channel would then prevent extra CICR-triggered releases in mature cardiomyocytes. However, hiPSC-CMs remain rather immature and are lacking the formation of T-tubules [26, 27]. This could potentially imply that the role of dyad calcium is dominated by general cytosolic calcium, obstructing the prevention of EATs by verapamil in hiPSC-CMS. The use of flecainide was applied in our experiments with a similar reasoning of indirectly limiting CICR. Flecainide is a NaV1.5 blocker, which would lower the cytosolic sodium concentration, reducing the influx of calcium via NCX1, eventually reducing the reactivation of RyR2. Interestingly, while the affinity of flecainide is much higher for Nav1.5 and several potassium channels [28], a direct blockade of RyR2 has also been proposed [29, 30]. Again, no decrease in EAT prevalence was observed after flecainide treatment in the patient cells, which implies improbability of the controversial RyR2 blockade. However, flecainide analogs specifically targeting only NaV1.5 have severely decreased effects on RyR2-induced calcium release, highlighting the efficacy of direct RyR2 binding by flecainide [31]. Dantrolene is originally a RyR1 (present in skeletal muscle) blocker, used for treating muscular spasticity and malignant hyperthermia [32]. However, it has been shown that dantrolene can also block RyR2 (the isoform primarily present in the heart) [33], and has proven to be effective in hiPSC-CM models of RyR2 muations [34, 35]. The binding of dantrolene to RyR2 is rather specific, where it is proposed to bind only the unzipped state of the protein in which the channel has an increased open probability, often caused by pathogenic genetic variations [36]. This would suggest that if dantrolene was effective in completely blocking the EATs, there would be a mechanistic link with RyR2 such as a pathogenic genetic variation or chemical interaction. We observed only a decrease in EAT amplitude and not their occurrence. Moreover, within the clinically analyzed gene panel for inherited arrhythmias (Table S2), we carefully checked the sequence of the RyR2 gene in the patient but did not find any aberrancies. This could explain the only mild effect of dantrolene being merely based on incomplete blockade. In line with the sequence analysis of RyR2, we also cross-checked the sequence of DPP6, a gene involved in regulation of the transient outward potassium current in Purkinje fibers. This because overactivity of this gene due to genetic variations has been associated with the occurrence of idiopathic VF originating from the Purkinje [37, 38]. Performing drugs safety and application screenings in hiPSC-CMs, especially in engineered tissues, has for some drugs been shown to be effective and comparable to expected clinical outcome in both healthy and diseased cells [39, 40]. Unfortunately, the drug interventions in this study stress the difficulties in testing therapeutic options in diseased hiPSC-CMs when there is no known or suggested cause of the disease. Not only is it difficult to evaluate which class of drugs could be relevant, our data also shows that intervening with indistinct calcium disturbances could exacerbate the phenotype. Further understanding of molecular pathogenesis or genetic involvement remains a prerequisite before assessment of patient-specific treatment option can be considered. In line with that, for an appropriate comparison with the calcium handling machinery in adult cardiomyocytes, it is of utmost importance that this aspect needs additional maturation in hiPSC-CM [41, 42]. Clinical translationability of experimental hiPSC-CM phenotyping Patient-specific disease phenotyping has become increasingly better and easier with the use and improvements of hiPSC-CMs. These cells can be widely implemented to investigate molecular and functional consequences of novel genetic variations and inherited cardiomyopathies [13, 43–46]. The majority of the experimental studies are performed to associate a genetic predisposition to a general clinical phenotype in a patient population. However, this instigates the discussion on the role of experimental phenotyping of pathological electrophysiology in the absence of a known genetic variation. In our case, we have identified an experimental phenotype in the hiPSC-CMs derived from the patient that was reminiscent of the observed clinical presentation, which could aid in the understanding of underlying mechanisms, supports the use of prescribed treatment options, and assists the vision of patient-tailored care in the future. However, the translationability of this disease model can partly be hampered by the mentioned immaturity of the hiPSC-CMs, or technical limitations such as spontaneous beating rates [47]. This is exemplified by the observed discrepancy between the interlinked duration of the AP and the CaT in the independently performed measurements. While this is relatively common for immature hiPSC-CMs that have been cultured for less than 90 days post-differentiation [48], future studies would benefit greatly from simultaneous optical AP and CaT measurements to study these electrophysiological parameters in concordance [49]. Nonetheless, the occurrence of these EATs is both pronounced and harmful, and an extensive collaboration between researchers and clinicians is required to determine the value of disease modeling and experimental phenotyping for patient care. Proposed future work on this specific case could expand on the role of temperature regulation by performing serial measurements, shifting from normothermic to hyperthermic and back, and quantifying the changes in EAT incidence. When this becomes feasible, hiPSCs could also be differentiated into cardiac Purkinje-like cells to improve compatibility with the presumed cell type origin of the electrical disturbances in the patient [50]. Additionally, more extensive pharmacological screenings could be performed, using e.g. quinidine and verticilide, to further establish a pathological mechanism. Conclusion Here, we studied a patient-specific case of scTdP, in which the patient has suffered from multiple episodes of VF. Generation of hiPSC-CMs of the patient successfully recapitulated the clinical electrophysiological phenotype that could potentially be explained by the occurrence of premature calcium releases in the cardiomyocytes of the patient. This study emphasizes the potential of hiPSC-CMs in studying cellular mechanisms and pharmacological interventions, while simultaneously describing the necessity for a delicate approach in translating the experimental results towards the clinics. Supplementary Information Additional file 1: Figure S1. Patient hiPSC clones characteristics. Three independent patient hiPSC clones were generated from isolated peripheral blood mononuclear cells. (A) FACS plots of SSEA4, Nanog, and OCT3/4 markers. (B) Karyo-sequencing profiles. Figure S2. Example recordings of calcium transients in healthy and patient lines. Example calcium transient measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during hyperthermia, indicating the occurrence of early after calcium transients. Figure S3. Example recordings of action potentials in healthy and patient lines. Example action potential measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during normo- and hyperthermia, indicating the shorter action potentials in the patient and both normo- and hyperthermia. Figure S4. Gene expression changes underlying disturbed calcium handling. Quantification of mRNA expression of genes involved in cardiac electrophysiology in hiPSC-CMs from the patient (red) and a healthy control (black). Generally, mRNA expression of electrophysiologically crucial genes was downregulated in the patient. Figure S5. Example recordings of calcium transients after pharmacological intervention. Example calcium transient measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during hyperthermia after vehicle (DMSO), verapamil (5.5 µM), or dantrolene (10 µM) administration, indicating the diminished amplitude of early after calcium transients in the patient. Acknowledgements The authors declare that they have not use AI-generated work in this manuscript. Abbreviations Action potential Action potential duration Calcium transient Early after depolarization Early after transient Human induced pluripotent stem cell derived cardiomyocytes Implantable cardioverter defibrillator Sodium-calcium exchanger Ryanodine receptor Sudden cardiac death Short-coupled Torsade de Pointes Sarco-endoplasmic reticulum calcium ATPase Sarco-endoplasmic reticulum Ventricular fibrillation Author contributions F.W.A, M.B., and T.A.B.v.V. Conceived the project. W.B.v.H., E.v.R., and T.A.B.v.V. Designed the experiments. J.M.K. and E.v.R. Provided materials. W.B.v.H., E.E.M.M., M.L.L., and J.M.K., Performed the experiments and analyzed the data. A.S.J.M.t.R., F.W.A, and M.B., Provided patient information and clinical background. W.B.v.H. and T.A.B.v.V. Wrote the initial manuscript. All authors read and approved the final submitted manuscript. Funding This work was supported by a grant from the Netherlands Cardio Vascular Research Initiative (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences (CVON-PREDICT2 2018-30). Further financial support is acknowledged from the foundation Vrienden van het UMC Utrecht. Availability of data and materials The datasets supporting the conclusions of this article are included within the article. Declarations Ethics approval and consent to participate (1) This study was part of the UNRAVEL RDP. (2) The project has been approved by the Biobank Board of the Medical Ethics Committee of the University Medical Center Utrecht. (3) The approval number is 12-387 UNRAVEL Biobank. (4) The project has been approved in 2018. Informed consent Informed consent was obtained from the patient for the participation in this study, including the production of hiPSC-CMs, performed experiments, and publication of the acquired data. Competing interests The authors declare that they have no competing interests. Footnotes Anneline S. J. M. te Riele: Member of the European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD-Heart (ERN GUARD HEART; http://guardheart.ern-net.eu). Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mimount Bourfiss and Toon A. B. van Veen are shared senior authors. References Associated Data Supplementary Materials Additional file 1: Figure S1. Patient hiPSC clones characteristics. Three independent patient hiPSC clones were generated from isolated peripheral blood mononuclear cells. (A) FACS plots of SSEA4, Nanog, and OCT3/4 markers. (B) Karyo-sequencing profiles. Figure S2. Example recordings of calcium transients in healthy and patient lines. Example calcium transient measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during hyperthermia, indicating the occurrence of early after calcium transients. Figure S3. Example recordings of action potentials in healthy and patient lines. Example action potential measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during normo- and hyperthermia, indicating the shorter action potentials in the patient and both normo- and hyperthermia. Figure S4. Gene expression changes underlying disturbed calcium handling. Quantification of mRNA expression of genes involved in cardiac electrophysiology in hiPSC-CMs from the patient (red) and a healthy control (black). Generally, mRNA expression of electrophysiologically crucial genes was downregulated in the patient. Figure S5. Example recordings of calcium transients after pharmacological intervention. Example calcium transient measurements performed in hiPSC-CMs from the patient (red) and a healthy control (black) during hyperthermia after vehicle (DMSO), verapamil (5.5 µM), or dantrolene (10 µM) administration, indicating the diminished amplitude of early after calcium transients in the patient. Data Availability Statement The datasets supporting the conclusions of this article are included within the article.